BackSoaring Eagle Acquisition Overview

Soaring Eagle Acquisition Accounts Payable

Track Soaring Eagle Acquisition's accounts payable ($9.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$9.57M
14.52% YoYΔ $-1.63M vs prior year quarter

Peer average

Loading

Soaring Eagle Acquisition Accounts Payable History

Loading

Soaring Eagle Acquisition vs. peers: Accounts Payable Comparison

Loading

Soaring Eagle Acquisition Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Soaring Eagle Acquisition (SRNG) FAQ

Soaring Eagle Acquisition's accounts payable stands at $9.6M as of June 2026. That compares with $11M in the prior-year period — down 14.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Soaring Eagle Acquisition reported $9.6M in accounts payable versus $11M a year earlier — a 14.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $11M in the prior-year period — down 14.5% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Soaring Eagle Acquisition's accounts payable evolved across reporting periods, while the comparison chart places SRNG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Soaring Eagle Acquisition's reading of $9.6M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.